FDA expands Anktiva approval to papillary-only BCG-unresponsive bladder cancer
- On 14 October 2026 the FDA expanded the approval of Anktiva (nogapendekin alfa inbakicept-pmln) with BCG for non-muscle invasive bladder cancer.
- Anktiva now covers high-grade papillary-only tumours, not just cases with carcinoma in situ (CIS).
- In QUILT-3.032, Anktiva produced a 62% complete response rate in 77 patients with CIS.
- In the papillary-only cohort of 80 patients, the company reported a 12-month disease-free survival of 58.2%.
The US Food and Drug Administration expanded the approval of ImmunityBio's Anktiva (nogapendekin alfa inbakicept-pmln) with BCG on 14 October 2026 for adults with BCG-unresponsive non-muscle invasive bladder cancer. It now includes patients with high-grade papillary-only tumours; since April 2024 it had been limited to carcinoma in situ (CIS) with or without papillary tumours.
The basis
Efficacy was previously shown in Cohort A of QUILT-3.032, 77 patients with CIS, where the complete response rate was 62% and 58% of responders stayed in response for 12 months or more. The FDA based the expansion on a review of available evidence: both tumour types are aggressive, often coexist and can be hard to tell apart. The application also included Cohort B, 80 patients with papillary-only disease, where the company reported a 12-month disease-free survival of 58.2%.
Also read: FDA grants accelerated approval to dostarlimab for dMMR/MSI-H locally advanced rectal cancer
Dosing and warnings
Anktiva is given with BCG into the bladder through a catheter once a week for 6 weeks, then continued based on response for up to 37 months. Common side effects include painful or frequent urination, urgency, blood in the urine and urinary tract infections. The label warns that delaying bladder removal in non-responders can allow the cancer to spread.
Sources: US Food and Drug Administration (FDA), AJMC
This story is relayed from the source named above; responsibility for its content rests with the original source.
FAQ
What is new in the Anktiva approval?
On 14 October 2026 the FDA expanded Anktiva with BCG to cover BCG-unresponsive non-muscle invasive bladder cancer with high-grade papillary-only tumours.
What was Anktiva approved for before?
Since April 2024 Anktiva had been approved for BCG-unresponsive bladder cancer with carcinoma in situ (CIS), with or without papillary tumours.
What results has Anktiva shown?
In QUILT-3.032, Anktiva gave a 62% complete response rate in CIS patients, and the company reported 58.2% 12-month disease-free survival in papillary-only patients.
How is Anktiva given?
Anktiva is given with BCG into the bladder through a catheter weekly for 6 weeks, then continued based on response for up to 37 months.
What are the common side effects of Anktiva?
The most common side effects of Anktiva are painful or frequent urination, urgency, blood in the urine and urinary tract infections.



